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The first embryonic stem cell (ESC) lines have been isolated at the beginning of the 1980s 
from the inner cell mass of mouse blastocysts (stage 5.5-7.5 days post-fertilization) with 
direct culture or immununosurgery by two groups of researchers working independently 
(mouse ESCs, mESCs, Evans & Kaufman, 1981; Martin 1981). It took more than a decade to 
obtain ESC lines from blastocysts of the primate rhesus monkey (Thomson et al., 1995), the 
common marmoset (Callithrix jacchus) (Thomson et al., 1996), human (hESCs; Thomson et 
al., 1998), dog (Hayes et al., 2008) and rat (Li et al., 2008; Buehr et al., 2008). 
ESCs are undifferentiated, pluripotent and self-renewable cells that can be maintained in 
vitro in the same undifferentiated status over extended periods of culture. They grow in 
colonies and possess a high nucleus/cytoplasm ratio (Figure 1a). ESCs are characterized by 
the expression of specific transcription factors (OCT-4, SOX2 and NANOG), and surface 
markers (TRA-1-60, TRA-1-81, SSEA-3 and SSEA-4 in hESCs, and also Ssea-1 in mESCs) 
(Figure 1b’ and c’), by high telomerase expression and alkaline phosphatase activity (Figure 
1d). If injected into a blastocyst, they are able to participate to foetal development and to the 
formation of the germ cell line; also, following their injection into immunodeficient mice, 
they form teratomas with derivatives of all three germ layers. Under appropriate in vitro 
culture conditions in suspension, ESCs form three-dimensional cell aggregates called 
embryoid bodies (EBs; Figure 1e), that differentiate into the three germ layers (ectoderm, 
mesoderm and endoderm; Figure 1f, g and h). Following the addition of bone 
morphogenetic protein 4 (BMP4) to the culture medium, it has been demonstrated that both 
hESCs (Xu et al. 2002) and mESCs (Hayashi et al., 2010) can differentiate into the 
trophoblast.  
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Because of their plasticity and potential to differentiate in all the cell types, ESCs represent 
an important tool for investigating early development for the study of genetic disease and as 
a cellular in vitro model for screening the effects of new drugs or xenobiotics; and in 
regenerative medicine and tissue replacement after injury or disease. At this regard, many 
disorders such as blood and immune-system related genetic diseases, cancer diabetes, 
Parkinson's disease and spinal cord injuries could be potentially treated using a pluripotent 
stem cell therapy, even if technical problems of graft-versus-host disease associated with 
allogenic stem cell transplantation (histocompatibility problems) are not negligible (Guyette 
et al., 2010; Marr et al., 2010; Arenas, 2010). In 2006, a new type of mouse pluripotent cells, 
with characteristics very similar to ESCs, has been developed by the group of Yamanaka 
(Takahashi & Yamanaka, 2006). These cells, called induced pluripotent stem cells (iPSCs), are 
the result of genome reprogramming by the ectopic expression of four transcription factors 
(Oct-4, Sox2, c-Myc and Klf4) of differentiated fibroblasts. iPSCs exhibit ESCs morphology and 
growth properties; they are pluripotent, undifferentiated and express ESCs markers. iPSCs 
have also been subsequently generated from human, rhesus monkey and rat adult primary 
fibroblasts (Takahashi et al., 2007; Liu et al., 2008; Li et al., 2009) and, more recently, from 
human adult blood cells (Loh et al., 2009) and rat bone marrow (Liao et al., 2009).  
 
 
Fig. 1. Mouse embryonic stem cells and their derived embryoid bodies. Morfology of mESC 
colonies (a); immunocytochemical detection of Oct-4 (b’) protein and Ssea-1 surface antigen 
(c’) expression;  alkaline phosphatase positive colonies (d); an embryoid body obtained after 
5 days of mESCs differentiation (e); mESCs differentiated into cells of the ectoderm layer, 
expressing the Nestin marker (f); mESCs differentiated into cells of the mesoderm layer, 
expressing the Flk-1 marker (g); mESCs differentiated into cells of the endoderm layer, 
observed by histological examination of endodermal epithelial cells (arrow) 
2. Loss of genome stability, the importance and consequences for ESCs 
The mainteinance of the genomic stability is crucial for normal cell survival and cell growth. 
Genomic instability is a general term to describe the processes that can increase the rate of 
mutation of a population, enabling cells to develop new and aggressive phenotypes. Two are 
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the main mechanisms of instability: microsatellite and chromosomal instability (Lengauer et al., 
1997). Microsatellite instability involves simple DNA base changes or tandemly repeated 
nucleotide sequences (microsatellite regions), whereas chromosomal instability involves whole 
chromosomes or large portions of them that are gained, lost or rearranged.  
The maintenance of the correct chromosome complement is one of the most important 
necessity for ESCs, in particular for their possible therapeutical use. As other cell lines 
cultivated in vitro,  ESCs are prone to accumulate karyotype abnormalities during long 
period of culture, although their mutation frequency is about 100 times lower when 
compared to differentiated cells, suggesting that ESCs have specialized mechanisms to 
preserve their genome integrity (Tichy & Stambrook, 2008). 
3. Methods to study the chromosome complement  
A chromosome aberration is either an incorrect number of chromosomes (that can occur as a 
consequence of an error during cell division) or a structural abnormality in one or more 
chromosomes. There are many types of chromosome anomalies, which can be organized 
into two groups: numerical or structural (Figure 2). An abnormal number of chromosomes is 
called aneuploidy and occurs when either one or more chromosomes are missing or gained. 
A structural abnormality is defined when the normal chromosome structure is altered (e.g., 
deletion, duplication, translocation etc.).  
 
 
Fig. 2. Examples of numerical and structural chromosome abnormalities a mESC line. Reverted 
image of a DAPI-banded karyotype of a normal metaphase from a mESC line (a); numerical 
abnormal metaphase with a trisomy of chromosome 13 from a mESC line (b); structural 
chromosome abnormalities: metacentric chromosomes (c), chromosome fragment (d) dicentric 
chromosome (e), human chromosome 3 insertion (f), mouse chromosome 6 deletion (f) 
Various types of methods are currently available to determine the chromosome complement 
and evaluate its integrity. Each technique has advantages and disadvantages in terms of 
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sensitivity, resolution and costs (Catalina et al., 2007). Classical simple banding techniques 
allow the regular check of the chromosome composition of the cell lines. For example, G- 
(Giemsa-stain) and DAPI-banding, providing 300-400 stained bands, permit both the 
identification of uncorrect chromosome numbers (aneuploidies) and structural chromosome 
abnormalities (e.g., translocations, deletions or insertions) of wide portions of chromosomes 
with a resolution of 5-10 Mb. Spectral karyotype (SKY technique) and multicolor fluorescent 
in situ hybridization (mFISH) represent an evolution of the conventional banding analysis 
(Schrock et al., 1996; Liyanage et al., 1996). Sky and mFISH allow the identification of each 
single chromosome with a higher resolution, approximately 1-2 Mb, when compared to 
classical cytogenetic methods and are usefull for the detection of submicroscopic deletions, 
insertions or DNA amplifications. However, to detect smaller genetic imbalances, the best 
techniques available at present are the array-based comparative genomic hybridization (array-
CGH; Sanlaville et al., 2005) and the single nucleotide polymorphism array (SNP-array; Peiffer 
et al., 2006). The resolution of these techniques allows the detection of tiny aberrations (from 1 
Mb to less than 100 kb) including homo- or hemizygous deletions, copy-neutral loss of 
heterozygosity, duplications and amplifications; however, these procedures are unable to 
evaluate the frequency within the cell population of a specific abnormality. Although these 
techniques shorten the whole screening procedure because they do not require cells blocked at 
metaphase, somehow, the costs of the equipment and consumables are an obstacle for their 
routinary use in the monitoring of chromosome stability.  
In summary, the combination of both conventional and molecular cytogenetic technologies 
represents the best approach for the evaluation of the genomic integrity of a ESC lines. 
4. Chromosome variation in human, primate and rodent ESCs 
In the literature, a fine characterization of abnormalities and a potential explanation about 
their onset are present for both human and mouse ESCs. Some information is available also 
for iPSC cells, non-human primates and rat ESCs. A brief overview is reported below.  
Human 
hESCs can accumulate abnormalities when maintained in culture for few months. The 
chromosome changes observed affect more frequently chromosomes 12, 17, 20 and X. The 
reason why these chromosomes are more frequently involved is not clear, although it has 
been proposed that their alterations confer a selective and/or proliferative advantage to 
cells carring the mutations. The gain of part or of the entire chromosome 12 has been found 
in many hESC lines (i.e., BG01, BG02, BG03, H1, H7, H9, H14 and HS181) and observed in 
many indipendent laboratories (Brimble et al., 2001; Draper et al., 2004; Mitalipova et al., 
2005; Ludwig et al., 2006; Imreh et al., 2006). The presence of an additional copy of 
chromosome 17 is another frequent abnormality found in hESCs (Brimble et al., 2001; 
Mitalipova et al., 2005). Sometimes associated with the gain of chromosome 12, the gain of 
the q arm of the chromosome 17 has been observed (Draper et al., 2004). Even if it is not 
really clear why these chromosomes are frequently involved in hESCs karyotypic changes, it 
has been suggested that the increased dosage of proteins coded by some genes located on 
chromosomes 12 and 17 could confer a selective advantage to cells carring these mutations. 
Human Stella-related (STELLAR), NANOG, the Growth differentiation factor-3 (GDF3) are 
stem cell pluripotency markers located on chromosome 12p (Clark et al., 2004) whose over-
expression may participate to the maintainance of the pluripotent status (Spits et al., 2008). 
Similarly, the over-expression of BIRC5 (that encodes for the anti-apoptotic survivin protein; 
Blum et al., 2009) or of hsa-mir-21 microRNA (involved in tumorigenesis, cancer 
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progression and a regulator of the anti-apoptotic BCL2 gene; Caldas & Brenton, 2005), both 
located on chromosome 17, may confer a proliferation advantage. 
The trisomy of chromosomes 12 and/or 17 is often associated with the X chromosome 
trisomy (Brimble et al., 2004; Inzunza et al., 2004; Mitalipova et al., 2005; Ludwig et al., 2006). 
Recently, Navarro and colleagues have demonstrated that in mESC the three pluripotency 
factors (Nanog, Oct4 and Sox2) bind and repress Xist, the master regulator of X inactivation, 
but it is not clear how the trisomy of this chromosome could confer a proliferative or 
selective advantage to cells (Navarro et al., 2008).  
The gain of the entire or a part of chromosome 20 is an other typical chromosomal variation 
in hESCs (Rosler et al., 2004; Baker et al., 2007; Maitra et al., 2005; Spits et al., 2008; Lefort et 
al., 2008; Werbowetski-Ogilvie et al., 2009). It is known that the amplification of the region 
20q11.2 is recurrent in many types of cancer (melanoma, Koynova et al., 2007; breast, Guan 
et al., 1996; lung, Tonon et al., 2005; bladder, Hurst et al., 2004) and the possible candidate 
genes that can increase cell proliferation, are BCL2L1, directly involved in cell death and 
proliferation, DNMT3B, important for the correct imprinting, and POFUT1, which is 
indispensable for NOTCH cascade signaling activation. 
At present only a handful of papers has been published on the genomic integrity of human 
iPSCs. These pluripotent cells (derived from human adult fibroblasts; Takahashi et al., 2007; 
Lowry et al., 2008) usually own a normal karyotype during the early culture passages and 
they lack of hot spot instability regions. However, continuous passaging of iPSCs (e.g. 
derived from keratinocytes) resulted in the appearance of chromosomal abnormalities 
(46,XY,t(17;20)(p13;p11.2)) in 70% of the cells after 13 passages, involving the same 
chromosomes 17 and/or 20 frequently detected in hESCs (Aasen et al., 2008). Using human 
CGH Arrays, Chin and collaborators have observed few karyotypic alterations (the 
duplication of part of chromosome 8) in a late-passage (passage 44) in an iPSC line derived 
from a fibroblast line (Chin et al., 2009). 
Non-human primates 
Non-human primate ESC (nhpESC) lines are an important research tool for basic and 
applicative research. The rhesus macaque is physiologically and phylogenetically similar to 
human, and, therefore, it is a clinically relevant animal model for biomedical research. Even 
if a number of ESCs lines have been established from rhesus monkey (Macaca mulatta), 
common marmoset (Callithrix jacchus) and cynomolgus monkey (Macaca fascicularis) 
(Thomson et al., 1995; Thomsom et al., 1996; Nakatsuji and Suemori, 2002), very few studies 
have described their chromosome complement.  
The little information available shows that using a serum-free medium and subculturing 
with trypsin, cynomolgus and rhesus monkey ESCs maintain a normal chromosome 
complement and pluripotency characterisitics even after over 1 year of continuous culture 
(Nakatsuji and Suemori, 2002). More recently, the cytogenetic analysis of 18 rhesus monkey 
ESC lines revealed that the majority (15) of them maintained a normal karyotype with a 
normal diploid chromosome number. The three unstable ESC lines (ORMES-1, -2, and -5) 
showed, even at low passages, structural abnormalities, such as translocations (t(11;16) and 
t(5;19) with der (18) t(1;18)), or invertions (inv (1)). It has been hypothesized that the 
collagenase-based dissociation technique, used for ORMES-1, -2, and -5, may have 
contributed to the onset of karyotypic abnormalities in these cell lines (Mitalipov et al., 
2006). 
Mouse 
Unexpectedly, an accurate literature search showed that only a few papers described the 
genomic variation of mESCs during a long period of culture. In many mESC lines, no 
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recurrent chromosome abnormalities, but rather random alterations have been described by 
some laboratories (Longo et al., 1997; Guo et al., 2005; Sugawara et al. 2006; Rebuzzini et al., 
2008a; Rebuzzini et al., 2008b).  
The most complete analysis that has been made on mESCs was performed by Sugawara and 
colleagues (Sugawara et al., 2006). Following the observation of a total of 540 mESC lines, these 
authors showed that 66.5% of them presented a normal 2n=40 karyotype, whereas 15.9%, 
9.1%, and 2.8% showed modal chromosomal numbers of 41, 42, and 39, respectively. Among 
88 mESC lines, selected arbitrarily from the 540 lines, 60.2% showed a normal diploid 
karyotype, 51.4% showed a trisomy of chromosome 8, 14.3% had trisomy 8 in association with 
the loss of one sex chromosome, and 11.4% had trisomy 8 together with trisomy 11. 
The chromosome complement of ESCs is important in contributing both to somatic cell 
chimaerism and to germ line transmission. Euploid mESCs cultured in vitro for up to 20 
passages rapidly became severely aneuploid. Notably, when injected into the murine 
blastocyst, the percentage of euploid metaphases in the mESC clones correlates with the 
success obtained in the experiment: the more stable is the chromosome complement the 
higher is the number of chimeric embryos and pups obtained, and the higher is their the 
chimaerism. None of the mESC clones with more than 50% of chromosomally abnormal 
metaphases can be transmitted to the germline (Longo et al., 1997). Another confirmation 
that prolonged cell culture affects the normal diploid chromosomal composition of the 
population was reported by Guo and collaborators (Guo et al., 2005). Using mFISH analysis 
of four different mESC lines, they demonstrated that, although the morphology and the 
expression of stem markers appeared normal, two cell lines presented consistent numerical 
(41, 43, 44, sub- or tetraploid chromosome complement) and structural (trisomy of 
chromosomes 8, 12, 14 and 15, deletion of chromosome 6q and other aberrations with low 
frequency) aberrations (Guo et al., 2005). More recently, in our laboratory, we have analysed 
the chromosome complement of four indipendent mESC lines cultured for 3 months. In 
UPV04 mESC line about 60% of metaphases analysed were 2n=40 throughout the culture 
period. From passage 13, 50% of metaphases were euploid, with a correct chromosome 
complement and the remaining 50% showed gain or loss of entire chromosomes, both 
within the same passage and among different passages analysed. A very heterogeneous 
spectrum of abnormalites was described, indicating their continuous arising (Rebuzzini et 
al., 2008a). In other three mESC lines, named UPV02, UPV06 and UPV08, a progressive loss 
of euploid metaphases during culture has been observed and chromosome abnormalities, in 
particular metacentric chromosomes, accumulated at the latest passages analysed (passage 
31, 29 and 22 for UPV02, UPV06 and UPV08, respectively). We observed that in coincidence 
with, or few passages after, the drop of euploidy, the alkaline phosphatase activity, one 
important ESC marker, was partially or totally lost (Rebuzzini et al., 2008b).  
Rat 
The rat ESCs (rESCs) are an important resource for the study of disease models, however, 
despite several temptatives (Brenin et al., 1997; Vassilieva et al., 2000) they have been 
derived only very recently (Buehr et al., 2008; Ueda et al., 2008; Zhao et al., 2010). In two cell 
lines derived by Buehr and collegues in 2008, a trisomy for chromosome 9 was described 
both by CGH and by FISH analysis. In two rESC lines, recently established from Wistar rat 
blastocysts, a normal number of chromosomes was observed at low passages (before 
passage 11, approximately 40% exhibit a normal karyotype), but a rapid accumulation of 
chromosomal abnormalities was described at later passages (up to 16 passages) (Ueda et al., 
2008).  
www.intechopen.com
Genome Stability in Embryonic Stem Cells  
 
405 
5. Possible causes of chromosome variations during culture  
The variety of culture protocols applied in different laboratories working with ESCs may be 
the source of variations in cell differentiation and genome stability. Many papers published 
during the last decade described the presence of the feeder layer, the source of the serum 
(whether of animal or artificial origin) and the techniques used for cell passaging as the 
main and major factors affecting the maintainance of genome integrity during long culture 
periods. The majority of the data and information available on culture conditions are on 
human and mouse ESCs.  
Generally, ESCs are derived and maintained in vitro with a co-culture protocol on a feeder 
layer of mitotically inactivated fibroblast cells (mouse embryonic or immortalized 
fibroblasts) or on defined supportive matrixes (i.e., gelatin, fibronectin or matrigelTM). 
Whether using the former or the latter, genetic alterations were observed both in mESC and 
hESC lines (Cowan et al., 2004; Draper et al., 2004; Rosler et al., 2004; Mitalipova et al., 2005; 
Maitra et al., 2005; Guo et al., 2005; Longo et al., 2005; Imreh et al., 2006; Sugawara et al., 
2006; Rebuzzini et al., 2008a; Rebuzzini et al., 2008b), suggesting that the presence or 
absence of a supporting cellular feeder layer can not exclude the onset of aberrations in the 
ESCs genome.  
A fundamental component of the ESC medium is the serum of animal (calf or bovine) or 
artificial (knockout serum replacement of defined composition) origin. Despite the type of 
serum used, the genomic stability seems compromised. In a recent publication (Herszfeld et 
al., 2006) better results were obtained in the production of more stable hESCs when a serum 
replacement was used, likely because the use of artificial serum avoids the uncertainty of its 
composition which is frequently observed with animal-derived sera. 
The technique used to detach ESCs for passaging seems to play a major role in the 
maintenance of their genomic stability. ESC colonies can be dissociated mechanically (i.e., 
pipetting in and out and flushing the medium until the colonies are detached and 
disgregated), enzymatically or by manual (i.e., colonies are cut and removed using a blade) 
dissection. The manual and mechanical dissection are preferentially used during hESCs 
subculturing, as, being less aggressive, they better preserve the genome integrity (Buzzard 
et al., 2004; Mitalipova et al., 2005). The manual dissection can introduce a bias due to the 
choice of the colonies and the skill of the researcher (Lefort et al., 2000). A modified 
enzymatic dissociation solution, consisting of 0.25% trypsin, 0.1% collagenase IV, 20% KSR, 
and 1 mM CaCl2 in PBS, in combination with manual dissection for bulk passaging of hESCs 
has been proposed by Suemori and colleagues in 2006, demonstrating the maintenance of a 
normal chromosome complement after more than 100 passages in culture (Suemori et al., 
2006).  
6. Conclusions 
Because of their characteristics, ESCs represent an important and unique biological resource 
for cell therapy and regenerative medicine, but also they are more and more envisioned as 
opening new routes for pharmacological research (Laustriat et al., 2010). As addressed in 
this review, the mainteinance of a correct chromosome complement is fundamental for the 
employment of these cells and a constant monitoring of their stability is required. We have 
produced an up-to-date summary of the litterature available on chromosome complement in 
ESCs of several different species, highlighting the need for world-wide guidelines that 
would restrict a rather fragmented and puzzled scenario. Given the actual culture 
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conditions used, the preservation of ESCs with a stable karyotype appears to be difficult. 
Clearly, a single culture protocol for all the species under study does not appear feasible; 
instead, each model animal will necessitate its own specific guidelines. Based on our own 
experience mutuated with that gathered from the litterature described above, following is a 
summary of some important start points that we believe should be taken on board when 
aiming to obtain an ESC line with low chromosomal variations: 1) use of a serum with a 
chemically defined composition; 2) manual dissection of ESC colonies; 3) routine monitoring 
of the chromosome complement throughout the culture period. 
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